Acupuncture for Diabetic Gastroparalysis: a Randomized Controlled Trial (ADG-RCT)
Primary Purpose
Gastroparesis, Diabetes Complications
Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
acupoints combination 1
acupoints combination 2
sham acupoints combination
Sponsored by
About this trial
This is an interventional treatment trial for Gastroparesis
Eligibility Criteria
Inclusion Criteria:
- individuals who meet the diagnostic criteria of diabetes gastric paralysis.
- individuals between the ages of 18 and 60 years.
- individuals who meet blood glucose control standards: Fasting plasma glucose (FPG) ≤7. 8mmol/L; 2 hours plasma glucose (2hPG)≤13.6mmol/L.
- individuals who suffered for more than 3 years.
- individuals who treated with diet control or exercise or using hypoglycemic drug (except for α-glucosidase Inhibitor) on the basis of diet or exercise therapy and the dose stability must be last at least 3 months.
- individuals who receive no other treatments in the first 3 months.
- women who is at the age of childbearing age and take contraceptive measures.
- individuals who voluntarily agree with a study protocol and sign a written informed consent.
Exclusion Criteria:
- individuals who have reflux esophagitis;
- individuals who have gastroparesis after surgery;
- individuals who have acute complications with ketoacidosis and nonketotic hyperosmolar coma;
- individuals who have Acute cardiovascular and cerebrovascular diseases or Severe trauma or surgery, severe infection. Or who are pregnant or breastfeeding;
- individuals who have a history disease of myocardial infarction, acute coronary syndrome or coronary revascularization;
- individuals who have serious hepatobiliary disease, or AST and/or ALT 2 times greater than the upper limit of normal patients;
- individuals with kidney damage, and serum creatinine exceeds 140umol/L;
- individuals who have obvious blood system diseases (Any one of which can not be caught in line: Hb: male<110g/L, women<100g/L,WBC<3.5×109/L,PLT<80×109/L).
- individuals who have a problem of blood press:SBP≥180mmHg,DPB≥100mmHg;
- individuals who have cancer or other serious progressive wasting disease, and easy to infection and bleeding;
- individuals who have peptic ulcer or other organic disease confirmed by esophagogastroduodenoscopy;
- individuals unwilling to meet the testing and exacerbations,or have serious complications in the test;
- individuals who have taking α-glucosidase inhibitor drug in the past four weeks.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Active Comparator
Sham Comparator
Arm Label
acupoints combination 1
acupoints combination 2
sham acupoints combination
Arm Description
acupoints comination 1 includes the specific acupoint ST36 (Zusanli) and a local acupoint CV12 (Zhongwan).
acupoints comination 2 includes the specific acupoint ST36 (Zusanli) and a distal acupoint PC6(Neiguan).
sham acupoints combination includes the specific acupoint ST36 (Zusanli) and a sham acupoint.
Outcomes
Primary Outcome Measures
the score of GCSI
GCSI means gastroparesis cardinal symptom index
Secondary Outcome Measures
Gastric emptying time
gastrin concentrations
motilin concentrations
Full Information
NCT ID
NCT02594397
First Posted
October 31, 2015
Last Updated
October 31, 2015
Sponsor
The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine
1. Study Identification
Unique Protocol Identification Number
NCT02594397
Brief Title
Acupuncture for Diabetic Gastroparalysis: a Randomized Controlled Trial
Acronym
ADG-RCT
Study Type
Interventional
2. Study Status
Record Verification Date
September 2015
Overall Recruitment Status
Unknown status
Study Start Date
December 2015 (undefined)
Primary Completion Date
December 2016 (Anticipated)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine
4. Oversight
5. Study Description
Brief Summary
The purpose of this study is to determine whether the different combination of acupoints have different effect on diabetic gastroparalysis.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gastroparesis, Diabetes Complications
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
210 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
acupoints combination 1
Arm Type
Experimental
Arm Description
acupoints comination 1 includes the specific acupoint ST36 (Zusanli) and a local acupoint CV12 (Zhongwan).
Arm Title
acupoints combination 2
Arm Type
Active Comparator
Arm Description
acupoints comination 2 includes the specific acupoint ST36 (Zusanli) and a distal acupoint PC6(Neiguan).
Arm Title
sham acupoints combination
Arm Type
Sham Comparator
Arm Description
sham acupoints combination includes the specific acupoint ST36 (Zusanli) and a sham acupoint.
Intervention Type
Other
Intervention Name(s)
acupoints combination 1
Intervention Type
Other
Intervention Name(s)
acupoints combination 2
Intervention Type
Other
Intervention Name(s)
sham acupoints combination
Primary Outcome Measure Information:
Title
the score of GCSI
Description
GCSI means gastroparesis cardinal symptom index
Time Frame
4 weeks
Secondary Outcome Measure Information:
Title
Gastric emptying time
Time Frame
4 weeks
Title
gastrin concentrations
Time Frame
4 weeks
Title
motilin concentrations
Time Frame
4 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
individuals who meet the diagnostic criteria of diabetes gastric paralysis.
individuals between the ages of 18 and 60 years.
individuals who meet blood glucose control standards: Fasting plasma glucose (FPG) ≤7. 8mmol/L; 2 hours plasma glucose (2hPG)≤13.6mmol/L.
individuals who suffered for more than 3 years.
individuals who treated with diet control or exercise or using hypoglycemic drug (except for α-glucosidase Inhibitor) on the basis of diet or exercise therapy and the dose stability must be last at least 3 months.
individuals who receive no other treatments in the first 3 months.
women who is at the age of childbearing age and take contraceptive measures.
individuals who voluntarily agree with a study protocol and sign a written informed consent.
Exclusion Criteria:
individuals who have reflux esophagitis;
individuals who have gastroparesis after surgery;
individuals who have acute complications with ketoacidosis and nonketotic hyperosmolar coma;
individuals who have Acute cardiovascular and cerebrovascular diseases or Severe trauma or surgery, severe infection. Or who are pregnant or breastfeeding;
individuals who have a history disease of myocardial infarction, acute coronary syndrome or coronary revascularization;
individuals who have serious hepatobiliary disease, or AST and/or ALT 2 times greater than the upper limit of normal patients;
individuals with kidney damage, and serum creatinine exceeds 140umol/L;
individuals who have obvious blood system diseases (Any one of which can not be caught in line: Hb: male<110g/L, women<100g/L,WBC<3.5×109/L,PLT<80×109/L).
individuals who have a problem of blood press:SBP≥180mmHg,DPB≥100mmHg;
individuals who have cancer or other serious progressive wasting disease, and easy to infection and bleeding;
individuals who have peptic ulcer or other organic disease confirmed by esophagogastroduodenoscopy;
individuals unwilling to meet the testing and exacerbations,or have serious complications in the test;
individuals who have taking α-glucosidase inhibitor drug in the past four weeks.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Mailan Liu, Dr.
Phone
86-731-88458187
Email
445007305@qq.com
First Name & Middle Initial & Last Name or Official Title & Degree
Ping Li
Email
472198992@qq.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Zenghui Yue, Prof.
Organizational Affiliation
Hunan University of Chinese Medicine
Official's Role
Study Chair
12. IPD Sharing Statement
Citations:
PubMed Identifier
32399130
Citation
Xuefen W, Ping L, Li L, Xiaoli C, Yue Z. A Clinical Randomized Controlled Trial of Acupuncture Treatment of Gastroparesis Using Different Acupoints. Pain Res Manag. 2020 Apr 25;2020:8751958. doi: 10.1155/2020/8751958. eCollection 2020.
Results Reference
derived
Learn more about this trial
Acupuncture for Diabetic Gastroparalysis: a Randomized Controlled Trial
We'll reach out to this number within 24 hrs